Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
9.46
-0.06 (-0.63%)
Mar 6, 2026, 1:18 PM EST - Market open
Seres Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Seres Therapeutics stock have an average target of 14.33, with a low estimate of 6.00 and a high estimate of 22. The average target predicts an increase of 51.48% from the current stock price of 9.46.
Analyst Consensus: Hold
* Price targets were last updated on Sep 24, 2025.
Analyst Ratings
The average analyst rating for Seres Therapeutics stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $22 | Strong Buy | Maintains | $14 → $22 | +132.56% | Sep 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $1.25 → $6 | Strong Buy → Hold | Downgrades | $1.25 → $6 | -36.58% | May 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +164.27% | Mar 20, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $20 → $15 | Strong Sell | Maintains | $20 → $15 | +58.56% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 | Strong Buy | Maintains | $200 | +2,014.16% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
272.00K
Revenue Next Year
n/a
from 272.00K
EPS This Year
0.43
from 0.02
Increased by 2,376.72%
EPS Next Year
-7.98
from 0.43
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 420,000 | n/a | ||
| Avg | 272,003 | n/a | ||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.81 | -8.05 | |
| Avg | 0.43 | -7.98 | |
| Low | 0.08 | -7.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 4,519.2% | - | |
| Avg | 2,376.7% | - | |
| Low | 347.9% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.